Advancing Human Health Through Precision Medicine
Driving the next generation of therapeutic solutions from molecular discovery to global distribution, powered by quantum simulation, AI-driven trial optimization, and rigorous clinical excellence.
From Discovery to Delivery
Aevum Zenth Pharmaceuticals operates at the forefront of modern drug development, leveraging cross-divisional synergies to accelerate breakthrough therapies. Our integrated platform combines high-throughput screening, quantum molecular modeling, and AI-predicted pharmacokinetics to reduce development timelines by up to 40%.
We maintain a dual-focus strategy: expanding our portfolio in high-unmet-need therapeutic areas while pioneering novel drug delivery systems and personalized medicine frameworks. Every compound in our pipeline is designed with patient outcomes, accessibility, and manufacturing scalability at its core.
Targeted Oncology
Next-gen CAR-T & bispecific antibodies
Neurodegenerative
Anti-amyloid & neuroinflammation modulators
Advanced Delivery
Lipid nanoparticles & transdermal microsystems
Rare Diseases
Orphan drug programs & gene editing
Targeting Unmet Medical Needs
Our portfolio spans critical disease categories, guided by epidemiological data, clinical partnerships, and patient advocacy insights.
Oncology & Immunology
Developing checkpoint inhibitors, tumor-agnostic therapies, and adaptive immune modulators for solid tumors and hematological malignancies.
Neurology & CNS
Addressing Alzheimer's, Parkinson's, and rare neurological disorders through blood-brain barrier penetration technologies and neuroprotective agents.
Cardiovascular & Metabolic
Novel PCSK9 inhibitors, GLP-1 receptor agonists, and targeted therapies for heart failure and metabolic syndrome.
Infectious Disease & Vaccines
Next-generation mRNA platforms, broad-spectrum antivirals, and rapid-response vaccine manufacturing capabilities.
Rare Diseases & Gene Therapy
Orphan drug development, CRISPR-based interventions, and viral vector platforms for monogenic disorders.
Autoimmune & Inflammatory
Selective JAK inhibitors, B-cell depleters, and targeted cytokine blockers for RA, MS, IBD, and psoriasis.
Development Progress & Milestones
Transparent tracking of our active compounds across discovery, preclinical, and clinical phases.
| Program | Indication | Mechanism | Phase | Target Readout |
|---|---|---|---|---|
ZTH-402 Next-gen PD-1/PD-L1 dual blocker |
Non-Small Cell Lung Cancer | Bispecific Antibody | Phase III | H1 2026 |
ZTH-887 Oral GLP-1/GIP agonist |
Type 2 Diabetes & Obesity | Small Molecule | Phase II | Q3 2025 |
ZTH-119 Anti-tau microtubule stabilizer |
Alzheimer's Disease | Neuroprotective | Phase II | Q4 2025 |
ZTH-554 Selective Sphingosine-1-Phosphate modulator |
Multiple Sclerosis | Immunomodulator | Phase III | 2026 |
ZTH-023 LNP-delivered CRISPR-Cas9 editor |
Hereditary Transthyretin Amyloidosis | Gene Editing | Phase I | 2027 |
ZTH-771 Broad-spectrum antiviral entry inhibitor |
Respiratory Viruses (Pre-vaccine) | Small Molecule | Preclinical | IND 2025 |
ZTH-900 First-in-class orphan enzyme replacement |
Lysosomal Storage Disorder | Protein Therapeutic | Approved | Commercialized |
Manufacturing, Quality & Distribution
Pharmaceutical-grade excellence from active pharmaceutical ingredients (API) to finished dosage forms, compliant with FDA, EMA, and PIC/S standards.
GMP Facilities
Three state-of-the-art manufacturing sites across North America, Europe, and Asia-Pacific, supporting sterile injectables, oral solids, and biologics.
Quality Assurance
Continuous process verification, PAT integration, and real-time release testing ensuring batch-to-batch consistency and regulatory compliance.
Global Distribution
Cold-chain logistics, temperature-controlled warehousing, and direct-to-patient fulfillment networks spanning 60+ countries.
Partner with Zenth Health Sciences
Whether you're an investigator, biotech collaborator, healthcare provider, or patient advocate, we're building the future of medicine together.